Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis

JACC: Cardiovascular Imaging

Volumn 1, Issue 5, 2008, Pages 624-634

  Winter, Patrick M ^a   Caruthers, Shelton D ^a,b   Zhang, Huiying ^a   Williams, Todd A ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b PHILIPS HEALTHCARE   (United States)

Author keywords

angiogenesis; fumagillin; molecular imaging; nanoparticle

Indexed keywords

ATORVASTATIN; FUMAGILLIN; GADOLINIUM PENTETATE; NANOPARTICLE; RHODAMINE; VITRONECTIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; COMBINATION CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG POTENTIATION; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOLOGY; HYPERLIPIDEMIA; LIPID DIET; LOADING DRUG DOSE; LOW DRUG DOSE; MICROVASCULATURE; MOLECULAR IMAGING; MONOTHERAPY; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; CARBOCYANINES; CYCLOHEXANES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FATTY ACIDS, UNSATURATED; HEPTANOIC ACIDS; HETEROCYCLIC COMPOUNDS, 1-RING; INTEGRIN ALPHAVBETA3; LIVER; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RABBITS; SESQUITERPENES; TIME FACTORS;

EID: 51549084986     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.06.003     Document Type: Article

References (38)

1. Moreno P.R., Purushothaman K.R., Fuster V., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110 (2004) 2032-2038
2. Moreno P.R., Purushothaman K.R., Sirol M., Levy A.P., and Fuster V. Neovascularization in human atherosclerosis. Circulation 113 (2006) 2245-2252
3. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25 (2005) 2054-2061
4. Bjornheden T., Levin M., Evaldsson M., and Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 19 (1999) 870-876
5. Boyle J.J., Wilson B., Bicknell R., Harrower S., Weissberg P.L., and Fan T.P. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol 192 (2000) 234-242
6. Khatri J., Johnson C., Magid R., et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109 (2004) 520-525
7. de Boer O.J., van der Wal A.C., Teeling P., and Becker A.E. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization?. Cardiovasc Res 41 (1999) 443-449
8. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567-572
9. Girona J., La Ville A.E., Sola R., Plana N., and Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83 (1999) 846-851
10. Kimura M., Kurose I., Russell J., and Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 17 (1997) 1521-1526
11. Verhoeven B.A., Moll F.L., Koekkoek J.A., et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 37 (2006) 2054-2060
12. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
13. Sukhova G.K., Williams J.K., and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 1452-1458
14. Koutouzis M., Nomikos A., Nikolidakis S., et al. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 192 (2007) 457-463
15. Kolodgie F.D., Narula J., Yuan C., Burke A.P., Finn A.V., and Virmani R. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy?. J Am Coll Cardiol 49 (2007) 2093-2101
16. Kamba T., and McDonald D.M. Mechanisms of adverse effects of antiVEGF therapy for cancer. Br J Cancer 96 (2007) 1788-1795
17. Winter P.M., Morawski A.M., Caruthers S.D., et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108 (2003) 2270-2274
18. Winter P., Neubauer A., Caruthers S., et al. Endothelial alpha(nu)beta(3)-integrin targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2103-2109
19. Winter P.M., Schmieder A.H., Caruthers S.D., et al. Minute dosages of alpha(nu)beta(3)-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J 22 (2008) 2758-2767
20. Sadeghi M.M., Krassilnikova S., Zhang J., et al. Detection of injury-induced vascular remodeling by targeting activated alphaνbeta3 integrin in vivo. Circulation 110 (2004) 84-90
21. Hu G., Lijowski M., Zhang H., et al. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer 120 (2007) 1951-1957
22. Liu S., Widom J., Kemp C.W., Crews C.M., and Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282 (1998) 1324-1327
23. Arfin S.M., Kendall R.L., Hall L., et al. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci U S A 92 (1995) 7714-7718
24. Wang J., Lou P., and Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 77 (2000) 465-473
25. Griffith E.C., Su Z., Niwayama S., Ramsay C.A., Chang Y.H., and Liu J.O. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci U S A 95 (1998) 15183-15188
26. Bhargava p., Marshall J.L., Rizvi N., et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5 (1999) 1989-1995
27. Kudelka A.P., Verschraegen C.F., and Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 338 (1998) 991-992
28. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., and Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999) 1653-1655
29. Broome D.R. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66 (2008) 230-234
30. Cheresh D.A. Integrins in thrombosis, wound healing and cancer. Biochem Soc Trans 19 (1991) 835-838
31. Friedlander M., Theesfeld C.L., Sugita M., et al. Involvement of integrins alpha ν beta 3 and alpha ν beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 93 (1996) 9764-9769
32. De Nichilo M., and Burns G. Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha ν integrin expression on cultured human macrophages. Proc Natl Acad Sci U S A 90 (1993) 2517-2521
33. Helluin O., Chan C., Vilaire G., Mousa S., DeGrado W.F., and Bennett J.S. The activation state of alphaνbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem 275 (2000) 18337-18343
34. Itoh H., Nelson P., Mureebe L., Horowitz A., and Kent K. The role of integrins in saphenous vein vascular smooth muscle cell migration. J Vasc Surg 25 (1997) 1061-1069
35. Doyle B., and Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 49 (2007) 2073-2080
36. Khurana R., Simons M., Martin J.F., and Zachary I.C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112 (2005) 1813-1824
37. Takaya N., Yuan C., Chu B., et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111 (2005) 2768-2775
38. Raman S.V., Winner M.W., Tran T., et al. In vivo atherosclerotic plaque characterization using magnetic susceptibility distinguishes symptom-producing plaques. J Am Coll Cardiol Img 1 (2008) 49-57